Boston Scientific (NYSE:BSX) announced today that NICE issued guidance supporting the use of pulsed field ablation (PFA) for treating AFib. The National Institute for Health and Care Excellence (NICE), which provides evidence-based recommendations to improve health and social care in the National Health Service (NHS) in England and Wales, reviewed … [Read more...] about NICE recommends Boston Scientific Farapulse pulsed field ablation tech
Boston Scientific
Boston Scientific wins expanded FDA nod for Farapulse PFA
Boston Scientific (NYSE: BSX) announced today that the FDA approved an expansion to the label of its Farapulse pulsed field ablation (PFA) system. Farapulse, one of the leading PFA systems for treating AFib, received a much-anticipated FDA approval last year. The system treats AFib by delivering pulsed field energy through a catheter to ablate … [Read more...] about Boston Scientific wins expanded FDA nod for Farapulse PFA
Boston Scientific completes SoniVie acquisition
Boston Scientific announced today that it completed its previously announced acquisition of SoniVie. In March, Boston Scientific announced that it agreed to acquire the intravascular ultrasound system developer. This acquisition brings Boston Scientific into the now-competitive renal denervation (RDN) space. Recor Medical received a landmark … [Read more...] about Boston Scientific completes SoniVie acquisition
Boston Scientific has positive Farapulse, Farapoint data
Boston Scientific today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) system. The company reported primary endpoints results from the second phase of ADVANTAGE AF, with findings published in Circulation. Investigators presented key findings at the second annual PFA Live Case Summit in San … [Read more...] about Boston Scientific has positive Farapulse, Farapoint data
Data backs Boston Scientific drug-eluting stent
Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the … [Read more...] about Data backs Boston Scientific drug-eluting stent
Boston Scientific Farapulse PFA system shows superiority in head-to-head study with Medtronic cryoablation system
Boston Scientific announced new study findings demonstrating the superiority of its Farapulse pulsed field ablation (PFA) system. Data published in the New England Journal of Medicine showed Farapulse's superiority in reducing atrial arrhythmia (AA) recurrence or treating symptomatic, drug-refractory paroxysmal atrial fibrillation (PAF) compared … [Read more...] about Boston Scientific Farapulse PFA system shows superiority in head-to-head study with Medtronic cryoablation system
Boston Scientific to acquire renal denervation company SoniVie
Boston Scientific (NYSE:BSX) announced today that it agreed to acquire intravascular ultrasound system developer SoniVie. Marlborough, Massachusetts-based Boston Scientific is a strategic investor in SoniVie, holding about a 10% equity stake. With this stake, the transaction features an upfront payment of approximately $360 million for the 90% … [Read more...] about Boston Scientific to acquire renal denervation company SoniVie
Boston Scientific reports first cases with next-gen Faraflex catheter
Boston Scientific today announced the completion of the first-ever cases with its Faraflex mapping and pulsed field ablation (PFA) catheter. This latest technology marks another milestone for the Farapulse PFA portfolio. Boston Scientific initially won FDA approval for Farapulse in January 2024 and has since reported a number of significant … [Read more...] about Boston Scientific reports first cases with next-gen Faraflex catheter
Boston Scientific wins CE mark for Farapulse Nav mapping tech
Boston Scientific announced today that it received CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software. Farawave Nav and the Faraview software make up part of the company’s Farapulse pulsed field ablation (PFA) system. Boston Scientific initially won FDA approval for Farapulse in January 2024. In doing so, it … [Read more...] about Boston Scientific wins CE mark for Farapulse Nav mapping tech
Boston Scientific makes IVL play with Bolt Medical acquisition
Boston Scientific (NYSE: BSX) announced today that it agreed to acquire intravascular lithotripsy (IVL) platform developer Bolt Medical. On a 100% basis — before considering an existing equity stake and other adjustments — the deal is valued at $600 million upfront with up to an additional $300 million upon achievement of certain regulatory … [Read more...] about Boston Scientific makes IVL play with Bolt Medical acquisition
